人間のグルカゴン受容体によるGsとGiの認識の構造的基礎
まとめ
構造的研究により,ヒトのグルカゴン受容体 (GCGR) が異なるGタンパク質に結合する方法が明らかになった. 受容体細胞内ループの重要な違いは,GsまたはGi1タンパク質結合の選択性を決定する.
科学分野:
- 生物化学
- 構造生物学
- 薬理学について
背景:
- クラスBのGタンパク質結合受容体 (GPCR) は重要な治療標的である.
- これらの受容体は主にGsヘトロトリメリックGタンパク質を通して信号を送るが,結合乱交性を示す.
- トランスデューサーの関与を理解することは 薬の開発に不可欠です
研究 の 目的:
- ヒトのグルカゴン受容体 (GCGR) に対するGタンパク質結合選択性の構造的基礎を解明する.
- GsとGi1Gタンパク質との異なった相互作用を調査する.
主な方法:
- 高解像度構造を決定するために,冷凍電子顕微鏡 (cryo-EM) が使用されました.
- 構造的発見を検証するために,変異性および機能的測定を用いた.
主要な成果:
- GsまたはGi1でグルカゴンに結合する2つの異なるGCGR構造が解消されました.
- Gs と Gi1 の両方が似たような開いた腔内に結合しますが,選択性は特定の相互作用によって引き起こされます.
- Gタンパク質の選択性の決定要因として,受容体の細胞内ループの適合的変異が特定されました.
- より大きな相互作用インターフェースはGs結合を好み,特定の相互作用はGi結合に影響する.
結論:
- この研究は,GCGRのGタンパク質結合選択性に関する原子レベルの洞察を提供します.
- 細胞内ループの形状は,トランスデューサーの関与を決定する重要な要因です.
- これらの発見は,GCGR信号の選択的調節器の設計のための構造的基礎を提供します.
関連する概念動画
Transducer Mechanism: G Protein–Coupled Receptors
3.6K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
3.6K
GPCRs Regulate Adenylyl Cylase Activity
7.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.0K
G Protein-coupled Receptors
16.1K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
Activation and Inactivation of G Proteins
10.4K
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
10.4K
Insulin: The Receptor and Signaling Pathways
2.4K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.4K
Glucagon-like Receptor Agonists
757
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
757


